secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042390
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx FDA partial clinical hold lifted for iMMagine-1; Q2 net loss $23.9M
---------------------------------------------------------------------------

- FDA lifted partial clinical hold on CART-ddBCMA Phase 2 iMMagine-1 trial after patient death and protocol modifications.
- Cash, cash equivalents, and marketable securities $506.5M; funds operations through BLA filing into 2026.
- Collaboration revenue of $14.3M from Kite partnership; R&D expenses $28.3M, G&A $15.5M.
- Net loss improved to $23.9M vs $30.8M in Q2 2022; preliminary iMMagine-1 data expected 2H 2024.
- Expanded bridging therapies allowed under revised protocol; all 17 previously enrolled patients dosed during hold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/0000950170-23-042390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000095017023042390/aclx-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer